



Prior Authorization
JOHNS HOPKINS HEALTHCARE (MEDICAID) Orilissa - Priority Partners MCO
This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Johns Hopkins Healthcare at 1-410-424-4607 . Please contact Johns Hopkins Healthcare at 1-888-819-1043 with questions regarding the Prior Authorization process. When conditions are met, we will authorize the coverage of Orilissa - Priority Partners MCO.

Drug Name (select from list of drugs shown) Orilissa (elagolix)
--

Quantity	Frequency	Strength
Route of Administration	Expected Length of Therapy	

Patient Information	
Patient Name:	_____
Patient ID:	_____
Patient Group No.:	_____
Patient DOB:	_____
Patient Phone:	_____

Prescribing Physician	
Physician Name:	_____
Physician Phone:	_____
Physician Fax:	_____
Physician Address:	_____
City, State, Zip:	_____

Diagnosis: _____	ICD Code: _____
-------------------------	------------------------

Comments: _____

Please circle the appropriate answer for each question.	
1. Is this request for continuation of therapy?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.]	
[If no, then skip to question 5.]	
2. Has the patient received the maximum recommended treatment course of 24 months?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, then no further questions.]	

3. Does the patient have a coexisting condition of dyspareunia, or moderate hepatic impairment (Child-Pugh Class B)?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, then no further questions.]	
4. Is there documentation showing a reduction of dysmenorrhea and non-menstrual pelvic pain?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: Documentation must be submitted. Plan coverage is limited to a maximum total treatment duration of 24-months.]	
[No further questions.]	
5. Is the requested drug being prescribed by a gynecologist?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, then no further questions.]	
6. Does the patient have any of the following: A) Pregnancy, B) Severe hepatic impairment (Child-Pugh C), C) Known osteoporosis, D) Concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, then no further questions.]	
7. Is the patient 18 years of age or older?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, then no further questions.]	
8. Is the requested drug being prescribed for management of moderate to severe pain associated with endometriosis?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: Documentation must be submitted.]	
[If no, then no further questions.]	
9. Does the patient have a documented trial and failure of at least two concurrent regimens consisting of a prescription strength nonsteroidal anti-inflammatory drug (NSAID) and a continuous (combination estrogen-progestin) hormonal contraceptive?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: Documentation must be submitted.]	
[If no, then no further questions.]	
10. Does the patient have liver disease?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, then no further questions.]	
11. Does the patient have a documented Child-Pugh score of A or B?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: Documentation must be submitted.]	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date